InflaRx N.V.
vilobelimab
SARS-CoV-2-induced acute respiratory distress syndrome (ARDS)
Resolved
7days ago
Approval decision · Jun 30, 2026
What's at stake
A final FDA approval decision on vilobelimab for SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) is expected Jun 30, 2026.
Primary source
· SEC 6-K
verified 13h ago
“In the U.S., GOHIBIC (vilobelimab) has been granted an Emergency Use Authorization by the Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving IMV [...] ly; our ”